Nexavar in Patients with Renal Cell Carcinoma
view presentation
Osu 2014 asco review puduvalli pres neuro-oncology
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone.
Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
II-SDV 2014 Development of Reports and Visualisations to Facilitate the Analysis and Transformation of the Clinical Trial Landscape into Actionable Intelligence (Diane Webb - Bizint,
Clinical Development in Asia Pacific and Japan Rolf Schuermann, M.D., Ph.D., Vice-President, Head of Global Clinical Development Women’s Healthcare, Bayer
Crizotinib a8081001 asco 2010 slides
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastrolearning®
2015 ASCO In Review - Updates for Colorectal Cancer Patients
CCO immune checkpoint_inhibitors_in_cancer_care
ASCO Review- 2015 What is new in breast cancer?
